Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options across a range of therapeutic categories including eye care, dermatology, and infectious disease prevention. Their lead product, XDEMVY™ (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is FDA-approved in the United States for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease in patients with Demodex mites. Learn more at TarsusRx.com.
Legend
Available Timeslot
Scheduled Appointment
Personal Appointments
Appointment Request
Blocked Timeslot
Restricted Timeslot